Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular modeling of natural and synthesized inhibitors against SARS-CoV-2 spike glycoprotein

Molecular modeling of natural and synthesized inhibitors against SARS-CoV-2 spike glycoprotein PurposeViral diseases increasingly endanger the world public health because of the transient efficacy of antiviral therapies. The novel coronavirus disease 2019 (COVID-19) has been recently identified as caused by a new type of coronaviruses. This type of coronavirus binds to the human receptor through the Spike glycoprotein (S) Receptor Binding Domain (RBD). The spike protein is found in inaccessible (closed) or accessible (open) conformations in which the accessible conformation causes severe infection. Thus, this receptor is a significant target for antiviral drug design.MethodsAn attempt was made to recognize 111 natural and synthesized compounds in order to utilize them against SARS-CoV-2 spike glycoprotein to inhibit Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using simulation methods, such as molecular docking. The FAF-Drugs3, Pan-Assay Interference Compounds (PAINS), ADME (absorption, distribution, metabolism, excretion) databases along with Lipinski’s rules were used to evaluate the drug-like properties of the identified ligands. In order to analyze and identify the residues critical in the docking process of the spike glycoprotein, the interactions of proposed ligands with both conformations of the spike glycoprotein was simulated.ResultsThe results showed that among the available ligands, seven ligands had significant interactions with the binding site of the spike glycoprotein, in which angiotensin-converting enzyme 2 (ACE2) is bounded. Out of seven candidate molecules, six ligands exhibited drug-like characteristics. The results also demonstrated that fluorophenyl and propane groups of ligands had optimal interactions with the binding site of the spike glycoprotein.ConclusionAccording to the results, our findings indicated the ability of six ligands to prevent the binding of the SARS-CoV-2 spike glycoprotein to its cognate receptor, providing novel compounds for the treatment of COVID-19. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Research on Biomedical Engineering Springer Journals

Molecular modeling of natural and synthesized inhibitors against SARS-CoV-2 spike glycoprotein

Download PDF
16 pages

Loading next page...
 
/lp/springer-journals/molecular-modeling-of-natural-and-synthesized-inhibitors-against-sars-Q2UtTYrglJ
Publisher
Springer Journals
Copyright
Copyright © Sociedade Brasileira de Engenharia Biomedica 2021
ISSN
2446-4732
eISSN
2446-4740
DOI
10.1007/s42600-020-00122-3
Publisher site
See Article on Publisher Site

Abstract

PurposeViral diseases increasingly endanger the world public health because of the transient efficacy of antiviral therapies. The novel coronavirus disease 2019 (COVID-19) has been recently identified as caused by a new type of coronaviruses. This type of coronavirus binds to the human receptor through the Spike glycoprotein (S) Receptor Binding Domain (RBD). The spike protein is found in inaccessible (closed) or accessible (open) conformations in which the accessible conformation causes severe infection. Thus, this receptor is a significant target for antiviral drug design.MethodsAn attempt was made to recognize 111 natural and synthesized compounds in order to utilize them against SARS-CoV-2 spike glycoprotein to inhibit Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using simulation methods, such as molecular docking. The FAF-Drugs3, Pan-Assay Interference Compounds (PAINS), ADME (absorption, distribution, metabolism, excretion) databases along with Lipinski’s rules were used to evaluate the drug-like properties of the identified ligands. In order to analyze and identify the residues critical in the docking process of the spike glycoprotein, the interactions of proposed ligands with both conformations of the spike glycoprotein was simulated.ResultsThe results showed that among the available ligands, seven ligands had significant interactions with the binding site of the spike glycoprotein, in which angiotensin-converting enzyme 2 (ACE2) is bounded. Out of seven candidate molecules, six ligands exhibited drug-like characteristics. The results also demonstrated that fluorophenyl and propane groups of ligands had optimal interactions with the binding site of the spike glycoprotein.ConclusionAccording to the results, our findings indicated the ability of six ligands to prevent the binding of the SARS-CoV-2 spike glycoprotein to its cognate receptor, providing novel compounds for the treatment of COVID-19.

Journal

Research on Biomedical Engineering – Springer Journals

Published: Mar 1, 2022

Keywords: Coronavirus 2019; Spike glycoprotein; Molecular docking; Fluorophenyl; Propane

References

  • New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays
    Baell, JB; Holloway, GA
  • Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
    Belouzard, S; Chu, VC; Whittaker, GR
  • The Protein Data Bank
    Berman, HM
  • The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex
    Bosch, BJ; van der Zee, R; de Haan, CAM; Rottier, PJM
  • Etravirine
    Croxtall, JD
  • Origin and evolution of pathogenic coronaviruses
    Cui, J; Li, F; Shi, Z-L
  • Antimicrobial activity of flavonoids
    Cushnie, TT; Lamb, AJ
  • SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
    Daina, A; Michielin, O; Zoete, V
  • Biosynthesis and regulation of phenylpropanoids in plants
    Deng, Y; Lu, S
  • The spike protein of SARS-CoV—a target for vaccine and therapeutic development
    Du, L
  • Modeling of loops in protein structures
    Fiser, A; Do, RKG
  • Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission
    Graham, RL; Baric, RS
  • Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China
    Guan, Y; Zheng, BJ; He, YQ; Liu, XL; Zhuang, ZX; Cheung, CL; Luo, SW; Li, PH; Zhang, LJ; Guan, YJ; Butt, KM; Wong, KL; Chan, KW; Lim, W; Shortridge, KF; Yuen, KY; Peiris, JS; Poon, LL
  • Cellular entry of the SARS coronavirus
    Hofmann, H; Pöhlmann, S
  • Clinical features of patients infected with 2019 novel coronavirus in Wuhan China
    Huang, C; Wang, Y; Li, X; Ren, L; Zhao, J; Hu, Y; Zhang, L; Fan, G; Xu, J; Gu, X; Cheng, Z; Yu, T; Xia, J; Wei, Y; Wu, W; Xie, X; Yin, W; Li, H; Liu, M; Xiao, Y; Gao, H; Guo, L; Xie, J; Wang, G; Jiang, R; Gao, Z; Jin, Q; Wang, J; Cao, B
  • Principles of early drug discovery
    Hughes, JP; Rees, S; Kalindjian, SB; Philpott, KL
  • The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China
    Hui, DS; I Azhar, E; Madani, TA; Ntoumi, F; Kock, R; Dar, O; Ippolito, G; Mchugh, TD; Memish, ZA; Drosten, C; Zumla, A; Petersen, E
  • The structure-antioxidant activity relationship of dehydrodiferulates
    Jia, Y; He, Y; Lu, F
  • Pre-fusion structure of a human coronavirus spike protein
    Kirchdoerfer, RN; Cottrell, CA; Wang, N; Pallesen, J; Yassine, HM; Turner, HL; Corbett, KS; Graham, BS; McLellan, J; Ward, AB
  • Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis
    Kirchdoerfer, RN
  • Plant phenylpropanoids as emerging anti-inflammatory agents
    Korkina, L; Kostyuk, V; de Luca, C; Pastore, S
  • FAF-Drugs3: a web server for compound property calculation and chemical library design
    Lagorce, D; Sperandio, O; Baell, JB; Miteva, MA; Villoutreix, BO
  • Receptor recognition mechanisms of coronaviruses: a decade of structural studies
    Li, F
  • Structure, function, and evolution of coronavirus spike proteins
    Li, F
  • Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2
    Li, W; Greenough, TC; Moore, MJ; Vasilieva, N; Somasundaran, M; Sullivan, JL; Farzan, M; Choe, H
  • Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
    Li, F; Li, W; Farzan, M; Harrison, SC
  • Lead-and drug-like compounds: the rule-of-five revolution
    Lipinski, CA
  • Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    Lipinski, CA; Lombardo, F; Dominy, BW; Feeney, PJ
  • Bat-to-human: spike features determining ‘host jump’of coronaviruses SARS-CoV, MERS-CoV, and beyond
    Lu, G; Wang, Q; Gao, GF
  • Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
    Lu, R; Zhao, X; Li, J; Niu, P; Yang, B; Wu, H; Wang, W; Song, H; Huang, B; Zhu, N; Bi, Y; Ma, X; Zhan, F; Wang, L; Hu, T; Zhou, H; Hu, Z; Zhou, W; Zhao, L; Chen, J; Meng, Y; Wang, J; Lin, Y; Yuan, J; Xie, Z; Ma, J; Liu, WJ; Wang, D; Xu, W; Holmes, EC; Gao, GF; Wu, G; Chen, W; Shi, W; Tan, W
  • Computational approaches towards the rational design of drug-like compound libraries
    Matter, H; Barighaus, KH; Naumann, T; Klabunde, T; Pirard, B
  • Tools for integrated sequence-structure analysis with UCSF chimera
    Meng, EC; Pettersen, EF; Couch, GS; Huang, CC; Ferrin, TE
  • Molecular docking: a powerful approach for structure-based drug discovery
    Meng, X
  • Flavonoids: an overview
    Panche, A; Diwan, A; Chandra, S
  • UCSF chimera—a visualization system for exploratory research and analysis
    Pettersen, EF; Goddard, TD; Huang, CC; Couch, GS; Greenblatt, DM; Meng, EC; Ferrin, TE
  • Flavonoids as antioxidants
    Pietta, P-G
  • Flavonoids: promising anticancer agents
    Ren, W; Qiao, Z; Wang, H; Zhu, L; Zhang, L
  • Synthesis and antimicrobial activity of 2-fluorophenyl-4, 6-disubstituted [1, 3, 5] triazines
    Saleh, M; Abbott, S; Perron, V; Lauzon, C; Penney, C; Zacharie, B
  • Rossicasins a, B and rosicaside F, three new phenylpropanoid glycosides from Boschniakia rossica
    Shyr, M-H; Tsai, T-H; Lin, L-C
  • Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2
    Song, W; Gui, M; Wang, X; Xiang, Y
  • AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading
    Trott, O; Olson, AJ
  • Middle East respiratory syndrome and severe acute respiratory syndrome
    Vijay, R; Perlman, S
  • Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy
    Walls, AC; Tortorici, MA; Frenz, B; Snijder, J; Li, W; Rey, FA; DiMaio, F; Bosch, BJ; Veesler, D
  • Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein
    Walls, AC; Park, YJ; Tortorici, MA; Wall, A; McGuire, AT; Veesler, D
  • Comparative protein structure modeling using MODELLER
    Webb, B; Sali, A
  • Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus
    Woo, PC; Lau, SK; Lam, CS; Lau, CC; Tsang, AK; Lau, JH; Bai, R; Teng, JL; Tsang, CC; Wang, M; Zheng, BJ; Chan, KH; Yuen, KY
  • Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
    Yan, R; Zhang, Y; Li, Y; Xia, L; Guo, Y; Zhou, Q
  • Bioactivities and clinical applications of flavonoids
    Zhou, X; Li, H-j
  • Prospects for a MERS-CoV spike vaccine
    Zhou, Y; Jiang, S; Du, L